Related Experiment Videos
New nucleoside analogues for chronic hepatitis B
S W Schalm1, R A de Man, R A Heijtink
1Department of Internal Medicine II, (Hepatology Section), Erasmus University, Rotterdam, The Netherlands.
Journal of Hepatology
|January 1, 1995
Summary
Researchers screened nucleoside analogues for hepatitis B virus, finding potent antivirals like lamivudine with few side effects, unlike fialuridine. Famciclovir also shows promise for hepatitis B treatment.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern.
- Development of effective antiviral therapies for chronic hepatitis B is crucial.
- Nucleoside analogues have emerged as a promising class of antiviral agents.
Purpose of the Study:
- To evaluate the efficacy and safety of nucleoside analogues against hepatitis B virus.
- To identify compounds with a high therapeutic index for HBV treatment.
- To assess the in vivo antiviral effects and tolerability of specific drugs.
Main Methods:
- In vitro screening of nucleoside analogues against HBV.
- Phase I and II clinical studies in patients with chronic hepatitis B.
- Evaluation of drug-induced mitochondrial dysfunction.
- Assessment of drug tolerance in liver transplant patients.
Main Results:
- Several nucleoside analogues demonstrated high therapeutic index in vitro.
- Fialuridine and lamivudine exhibited potent in vivo antiviral effects in chronic hepatitis B patients.
- Fialuridine was linked to severe mitochondrial dysfunction.
- Lamivudine showed minimal side effects.
- Famciclovir demonstrated effectiveness and good tolerance in liver transplant patients with recurrent HBV.
Conclusions:
- Nucleoside analogues are effective in treating chronic hepatitis B.
- Lamivudine is a well-tolerated and effective antiviral agent for HBV.
- Fialuridine's use is limited by severe mitochondrial toxicity.
- Famciclovir represents a potential therapeutic option for recurrent HBV post-transplantation.